Colin Lightfoot

B.Sc. Biomedical Science, M.Sc. Infection and Immunity

Colin graduated from the University of Chester with a B.Sc. in Biomedical Science in 2020. Since completing his undergraduate degree, he worked for NHS England as an Associate Practitioner, responsible for testing inpatients for COVID-19 on admission.

Recently Colin was a Study Assistant for Perfectus Biomed, where he grew cell lines and viruses for the testing of mainly commercial cleaning products. He recently completed an M.Sc. in Infection and Immunity at The University of Chester, where his main research focus was antibiotic resistance and the possibility of combatting this with bacteriophage therapy.

Articles from Colin

Canadian study estimates incidence rate of reinfection in healthcare workers

Canadian study estimates incidence rate of reinfection in healthcare workers

Researchers from various Canadian institutions document all cases of reinfection discovered during the first year of the project.

15 Feb 2022

Comparison of SARS-CoV-2 test performance by sample type and modality in close contacts of SARS-CoV-2 cases

Comparison of SARS-CoV-2 test performance by sample type and modality in close contacts of SARS-CoV-2 cases

In this study, researchers looked at how well molecular and antigen testing performed in symptomatic and asymptomatic close contacts of SARS-CoV-2 positive people.

10 Feb 2022

Measuring T cell responses to SARS-CoV-2 vaccination and infection in healthcare workers with two different assays

Measuring T cell responses to SARS-CoV-2 vaccination and infection in healthcare workers with two different assays

The purpose of this study was to compare the OI TSPOT with the in-house PITCH ELISpot for reporting T cell responses specific to SARS-CoV-2 spike and structural proteins.

10 Feb 2022

Effectiveness of COVID-19 vaccination 9 months post-vaccination for the population of Sweden

Effectiveness of COVID-19 vaccination 9 months post-vaccination for the population of Sweden

Researchers looked at the efficiency of COVID-19 vaccines in preventing infection, hospitalization, and death in the general population of Sweden over the first nine months following vaccination.

9 Feb 2022

Study finds strong evidence of extensive SARS-CoV-2 infection of white-tailed deer

Study finds strong evidence of extensive SARS-CoV-2 infection of white-tailed deer

The scientists tested samples collected from free-living and confined deer in Iowa to see if infection and subsequent transmission of SARS-CoV-2 in deer happens in nature.

9 Feb 2022

Swedish study shows fully vaccinated are protected against severe COVID-19

Swedish study shows fully vaccinated are protected against severe COVID-19

Researchers evaluate the risk of severe Omicron infections in several risk categories defined by sex, age, comorbidities, and vaccination status.

8 Feb 2022

SARS-CoV-2 entry at the cell surface facilitated by trypsin

SARS-CoV-2 entry at the cell surface facilitated by trypsin

Exogenous trypsin treatment boosts SARS-CoV-2 infection in Vero E6 cells and promotes viral multiplication in cultured cells.

1 Feb 2022

Study finds that high-dose convalescent plasma does not improve outcomes for severe COVID-19

Study finds that high-dose convalescent plasma does not improve outcomes for severe COVID-19

A randomized controlled trial assesses the efficacy and safety of high-dose convalescent plasma in the treatment of severe COVID-19.

1 Feb 2022

Research shows rapid antigen tests can detect SARS-CoV-2 variants, including Omicron

Research shows rapid antigen tests can detect SARS-CoV-2 variants, including Omicron

Researchers determined the analytical sensitivity of a CE-marked fast antigen with the SARS-CoV-2 Omicron, Delta, Alpha, and Gamma variants.

31 Jan 2022

Reduced neutralization against Omicron variant in fully immunized adolescents with BNT162b2 vaccine

Reduced neutralization against Omicron variant in fully immunized adolescents with BNT162b2 vaccine

Researchers compare the humoral immune response in adolescents and adults after being completely immunized with the Pfizer BNT162b2 vaccine.

28 Jan 2022

Previous
1
...
5
6
7
8
9
10
11
...
23
Next

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.